Pasithea Therapeutics Corp. — Director's Dealing 2022

Oct 21, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2022-10-21

Reporting Person: Marques Tiago (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-10-21	Common Stock	A	600	$1.08	Acquired	805600	Direct
2022-10-21	Common Stock	A	4400	$1.07	Acquired	810000	Direct